Under Fire for Risk/Efficacy Profile – Nuplazid Shows Potential for Treating Dementia-Related Psychosis

Under Fire for Risk/Efficacy Profile – Nuplazid Shows Potential for Treating Dementia-Related Psychosis

Source: 
CP Wire
snippet: 

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) announced on 9/10/18 publication of additional data from a Phase 2 single center, double-blind, placebo-controlled study to examine the safety and efficacy of pimavanserin (Nuplazid) for the treatment of psychosis in Alzheimer’s Disease Psychosis in The Journal of Prevention of Alzheimer’s Disease (JPAD).